Need for aligning the definition and reporting of cytokine release syndrome (CRS) in immuno-oncology clinical trials

As cancer immunotherapies continue to expand across all areas of oncology, it is imperative to establish a standardized approach for defining and capturing clinically important toxicities, such as cytokine release syndrome (CRS). In this paper, we provide considerations for categorizing the variety...

Descripción completa

Detalles Bibliográficos
Autores principales: Stewart, Mark D., McCall, Bruce, Pasquini, Marcelo, Yang, Allen S., Britten, Carolyn D., Chuk, Meredith, De Claro, R Angelo, George, Bindu, Gormley, Nicole, Horowitz, Mary M., Kowack, Eric, McCoy, Candice, Morrow, Phuong Khanh, Okoye, Emmanuel, Ricafort, Rosanna, Rossi, John, Sharon, Elad, Theoret, Marc, Vegni, Ferdinando, Yu, Tai, Allen, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721456/
https://www.ncbi.nlm.nih.gov/pubmed/35219582
http://dx.doi.org/10.1016/j.jcyt.2022.01.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721456/
https://www.ncbi.nlm.nih.gov/pubmed/35219582
http://dx.doi.org/10.1016/j.jcyt.2022.01.004

Ejemplares similares